LLY · Healthcare

ELI LILLY & Co

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-07

• Distribution Channels - Hims & HersImportance 34 · Surprise 42
  Eli Lilly agreed with Hims & Hers to offer its FDA-approved obesity drugs Zepbound and Foundayo through the telehealth platform. Eligible patients can access Lilly's self-pay prices, complete consultations, receive…

News · 2026-11-06

• Distribution Channels - Hims & HersImportance 34 · Surprise 42
  Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to offer Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers platform. Eligible patients with prescriptions from licensed…
• Distribution Channels - Telehealth & AmazonImportance 34 · Surprise 42
  Eli Lilly agreed with Hims & Hers to offer Zepbound (tirzepatide) and Foundayo (orforglipron) through the telehealth provider’s platform. Eligible patients can consult with a licensed provider, receive a prescription…
• Foghorn Collaboration TerminationImportance 31 · Surprise 42
  Foghorn Therapeutics announced it would not advance the FHD-909 and Selective SMARCA2 degrader programs developed in collaboration with Lilly. The report gives no financial terms or timing for the decision. It also…

News · 2026-11-05

• Clinical Trial ResultsImportance 34 · Surprise 42
  At ACR Convergence 2026, Lilly will present Phase 3 TRIUMPH-1 and TRIUMPH-4 results showing retatrutide reduced knee pain and weight in adults with knee osteoarthritis and obesity. Some participants reported no knee…
• Distribution Channels - Employer / Digital PartnersImportance 34 · Surprise 42
  LifeMD and Lilly announced an arrangement allowing LifeMD’s affiliated pharmacy to dispense and ship Lilly’s self-pay GLP-1 medicines directly to eligible patients nationwide. The medicines covered are Zepbound…

News · 2026-11-04

• Guidance and outlook - 2026 raiseImportance 70 · Surprise 60
  Eli Lilly raised its annual revenue forecast to $91 billion–$92 billion in its October 29 results. The revised forecast sets the company’s annual sales target at a range of $91 billion to $92 billion. The article links…
• Guidance and OutlookImportance 70 · Surprise 60
  Eli Lilly raised its annual revenue forecast to $91 billion–$92 billion in its October 29 results. The November 4 report said the higher target heightened questions about the durability of growth as competition in…
• Competition and Market Share - oral GLP-1Importance 32 · Surprise 24
  Novo Nordisk and Eli Lilly are contesting leadership in the oral GLP-1 market, with differing measures of early adoption. Novo CEO Mike Maziar Doustdar claims the Wegovy pill has 80% market share, arguing Lilly’s data…

News · 2026-11-03

• Guidance and OutlookImportance 74 · Surprise 68
  After reporting third-quarter 2026 results, Lilly raised its full-year revenue guidance to $91–92 billion from $85–87 billion. The updated range reflects strong underlying business performance, including demand for…
• Revenue Performance and MixImportance 64 · Surprise 56
  Eli Lilly’s third-quarter 2026 revenue rose 39% year over year to $24.40 billion, while adjusted EPS increased 7% to $7.48. Volume grew 53%, more than offsetting a 15% decline in realized prices. Mounjaro and Zepbound…
• Market Demand - Anti-ObesityImportance 57 · Surprise 64
  Third-party reporting said volume growth was 53%, more than offsetting a 15% decline in realized prices in the third quarter. Mounjaro and Zepbound were identified as Lilly’s primary growth engines, and both…

News · 2026-11-02

• Revenue Performance and MixImportance 75 · Surprise 64
  Eli Lilly reported quarterly revenue of $24.397 billion on October 29, with Mounjaro contributing $10.723 billion and Zepbound $5.352 billion. Together, the two medicines generated 65.9% of quarterly revenue,…
• Market Demand - GLP-1Importance 63 · Surprise 64
  A report on Lilly’s October 29 results said worldwide volume for its medicines rose 53%, while realized prices fell 15%. The combination points to strong demand alongside substantial pricing pressure. It specifically…
• Guidance and OutlookImportance 60 · Surprise 24
  The article reports that Lilly’s full-year 2026 revenue guidance is $91 billion to $92 billion. It says the outlook follows strong demand for Mounjaro and Zepbound, alongside a tradeoff between rising volume and lower…
• Product / Drug Pipeline ProgressImportance 34 · Surprise 42
  Lilly reported positive Phase 3 retatrutide data in type 2 diabetes, including a head-to-head trial against Ozempic. It also presented positive Phase 1 results for sofetabart mipitecan in ovarian cancer, where the…
• Product Pipeline - Lp(a)Importance 20 · Surprise 24
  The reported failure of Novartis’s experimental drug pelacarsen to reduce heart attack and stroke risk despite lowering Lp(a) levels raised questions about whether targeting Lp(a) can improve clinical outcomes. The…
• Competition and Market Share - OncologyImportance 13 · Surprise 6
  Sanofi expects its Dupixent franchise to capture most of the increased awareness generated by Lilly’s direct-to-consumer advertising for Ebglyss. The report notes that Ebglyss had faster sales growth in the third…

News · 2026-10-31

• Revenue Performance and MixImportance 85 · Surprise 92
  Eli Lilly reported a 39% year-over-year revenue increase in the third quarter of 2026. Surging demand for Mounjaro and Zepbound drove the increase, although the digest provides no product-level revenue breakdown. Lilly…
• Guidance and OutlookImportance 41 · Surprise 60
  Lilly raised its full-year revenue forecast following strong third-quarter results. The report does not specify the revised forecast amount or the prior guidance. It attributes the outlook change to strong results but…
• Market Demand - Anti-ObesityImportance 26 · Surprise 24
  The report attributes Eli Lilly’s strong third-quarter results to surging demand for its obesity and diabetes treatments. It names Mounjaro and Zepbound as the products driving that demand. No market-size, order, or…

News · 2026-10-30

• Revenue Performance and MixImportance 80 · Surprise 68
  Mounjaro and Zepbound generated more than $16 billion in combined global sales in Q3 2026, driving Lilly’s quarterly performance. Lilly raised its 2026 revenue guidance to $91 billion–$92 billion. Q3 2026 adjusted…
• Guidance and OutlookImportance 75 · Surprise 60
  Eli Lilly raised its 2026 revenue outlook to $91 billion-$92 billion. The range reflects management’s forward view for the full year; the digest does not specify a timeframe for the increase beyond 2026. The outlook is…
• Distribution Channels - Foundayo AccessImportance 34 · Surprise 42
  Lilly continued the global rollout of Foundayo, launching the drug in the U.K., Mexico and Saudi Arabia for people with obesity. In Mexico, the launch also covers people with type 2 diabetes. The company also said the…
• Medicare GLP-1 Bridge ProgramImportance 34 · Surprise 42
  Eli Lilly said it expanded U.S. access to obesity medicines through the Medicare GLP-1 Bridge Program. Management cited approximately 20 million seniors as the population for whom access was expanded. The report gives…
• Product Launch - FoundayoImportance 34 · Surprise 42
  Lilly continued the global rollout of Foundayo, launching it in the U.K., Mexico, and Saudi Arabia for people with obesity. The company also launched it in Mexico for people with type 2 diabetes. The report does not…
• Competition and market share - weight-lossImportance 17 · Surprise 24
  Third-party reporting said Lilly trial data showed retatrutide outperforming Novo Nordisk’s Ozempic. The report characterized the data as sharpening the competitive focus on Novo Nordisk as the company sets longer-term…

10-Q · 2026-10-29

• Acquired IPR&D ChargesImportance 83 · Surprise 82
  Acquired in-process research and development charges totaled $4.181 billion in the third quarter of 2026 and $7.541 billion for the first nine months, compared with $2.381 billion for the first nine months of 2025. The…
• Market Demand TrendsImportance 69 · Surprise 64
  Mounjaro revenue increased 41% in the U.S. and 93% outside the U.S. in the third quarter of 2026, with strong U.S. demand and international volume growth. Zepbound revenue increased 48% in the U.S., primarily on strong…
• Revenue Performance and MixImportance 68 · Surprise 56
  Revenue was $24.397 billion in the third quarter of 2026, up approximately 39% from $17.601 billion, and $67.170 billion for the first nine months, up approximately 46% from $45.887 billion. Third-quarter U.S. revenue…
• Incretin Revenue ConcentrationImportance 68 · Surprise 24
  Mounjaro, Zepbound, and Foundayo together generated 66% of Lilly's total revenue for the nine months ended September 30, 2026. The three medicines therefore represented more than two-thirds of revenue during that…
• Gross Margin DriversImportance 64 · Surprise 56
  Gross margin increased to $20.464 billion in the third quarter of 2026 from $14.593 billion a year earlier, and to $56.392 billion for the first nine months from $38.207 billion. Gross margin as a percentage of revenue…
• Acquisition / Partnership / DivestitureImportance 64 · Surprise 42
  Lilly paid $18.2 billion for business development activity during the first nine months of 2026, primarily for Centessa, Kelonia, AtaiBeckley, Orna, Ventyx, Curevo, and Ajax. In October 2026, the company acquired…
• Geographic Market Commentary - China & InternationalImportance 63 · Surprise 64
  Outside the U.S., Mounjaro revenue increased 93% in the third quarter and 153% over the first nine months of 2026, primarily from volume growth. Lower realized prices partly offset that growth, driven primarily by…
• Liquidity and Cash PositionImportance 60 · Surprise 40
  Cash and cash equivalents were $4.9 billion at September 30, 2026, down from $7.3 billion at December 31, 2025; total investments increased to $4.1 billion from $2.9 billion. Total debt was $49.5 billion at September…
• Operating Expense Trends - R&DImportance 59 · Surprise 48
  Research and development expense was $4.247 billion in the third quarter of 2026, up 23% year over year, and $11.576 billion for the first nine months, up 21%. Lilly attributed the increases to continued investment in…
• Income Tax Rate ChangesImportance 56 · Surprise 46
  The effective tax rate was 23.3% in the third quarter of 2026, compared with 22.8% in the third quarter of 2025, and 21.0% for the first nine months of 2026, compared with 19.8% in 2025. Income tax expense rose to…
• Operating Expense Trends - SG&AImportance 48 · Surprise 40
  Marketing, selling, and administrative expense was $3.125 billion in the third quarter of 2026, up 14% year over year, and $9.489 billion for the first nine months, up 19%. The nine-month increase was $1.526 billion…
• Manufacturing CapacityImportance 40 · Surprise 42
  Lilly has undertaken significant manufacturing expansion initiatives to support anticipated demand for current and prospective products. Additional capacity is expected to become operational over the next several…
• Capital Return ProgramImportance 37 · Surprise 6
  Lilly repurchased $4.3 billion of shares during the first nine months of 2026 under its $15.0 billion share repurchase authorization approved in December 2024. At September 30, 2026, $6.6 billion remained under the…
• Product Launch - FoundayoImportance 34 · Surprise 42
  Lilly launched Foundayo (orforglipron) in the U.S. in the second quarter of 2026 for obesity treatment and submitted it to the FDA for type 2 diabetes. Internationally, the company has submitted or launched…
• Medicare GLP-1 Bridge ProgramImportance 34 · Surprise 42
  Under the Medicare GLP-1 Bridge program, Medicare beneficiaries gained access to discounted Lilly obesity medicines from July 1, 2026 through December 31, 2027. Individual state Medicaid programs may separately choose…
• Inflation Reduction Act ImpactImportance 32 · Surprise 24
  The Inflation Reduction Act of 2022 requires HHS to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Government prices generally begin nine years after…
• Guidance and OutlookImportance 32 · Surprise 24
  Lilly expects near-term financial performance to be affected by the timing of potential additional regulatory approvals for orforglipron and by demand and uptake in new incretin channels and markets. It specifically…
• Supply Chain Tariff ImpactImportance 26 · Surprise 24
  The U.S. and other countries have imposed or aligned on tariffs, some of which are paused but could take effect quickly and unpredictably. Lilly and pharmaceuticals are exempt from certain tariffs, but the exemptions…
• FDA Compounding RestrictionsImportance 26 · Surprise 24
  Lilly says production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins continue, creating patient-safety concerns and potentially undermining the drug-approval process. The…

Earnings call · 2026-10-29

• Medicare GLP-1 Bridge ProgramImportance 34 · Surprise 42
  More than half a million people had filled a Lilly prescription through the Medicare GLP-1 Bridge Program since its July 1 launch, and seven out of ten new Bridge patients were starting on a Lilly obesity medicine.…
• Business Development / AcquisitionsImportance 34 · Surprise 42
  Management said Lilly has completed early-stage and clinical-stage deals during 2026, including clinical programs that are not at a very late stage. The company is using strong performance in its incretin and other…
• Strategic InitiativesImportance 34 · Surprise 42
  Management described a portfolio approach to obesity treatment, citing approximately 110 million people in the U.S. with obesity or overweight and a larger international population. It said Foundayo, tirzepatide,…
• Capital Return ProgramImportance 31 · Surprise 6
  Lilly distributed $1.5 billion of dividends in Q3 2026. It also executed $400 million in share repurchases during the quarter. The reported distributions and repurchases totaled $1.9 billion for Q3.
• ESG and SustainabilityImportance 31 · Surprise 42
  Lilly launched its Change the Course commitment, setting a goal to reach as many people with obesity and related diseases in resource-limited settings as in high-income countries before 2040. The commitment is a global…
• Long-Acting Incretin TechnologyImportance 26 · Surprise 30
  Lilly sees an opportunity for longer-acting incretins, particularly in a large category with substantial consumer involvement. Management said it is evaluating multiple clinical efforts using different technological…
• Pricing and Reimbursement PressureImportance 26 · Surprise 24
  Management expects U.S. commercial access to remain relatively stable through 2027, while Medicare and Medicaid are expected to be the main sources of expanded coverage. The increased share of patients in those…
• Product Pipeline Progress - InluriyoImportance 26 · Surprise 24
  Management said Inluriyo is performing well commercially as monotherapy and in combination with Verzenio, and highlighted a potential opportunity in the adjuvant setting through the EMBER-4 study. Lilly expects EMBER-4…
• Gross Margin DriversImportance 25 · Surprise 32
  Gross margin as a percentage of revenue increased 80 basis points year over year to 84.4% in Q3 2026. Favorable product mix and improved cost of production drove the increase. Lower realized prices partially offset…
• Operating Expense Trends - SG&AImportance 23 · Surprise 22
  Marketing, selling, and administrative expenses increased 14% year over year in Q3 2026. Lilly attributed the increase to promotional activities supporting current and planned product launches. The spending supported…
• Market Demand - Anti-ObesityImportance 20 · Surprise 24
  Lilly described a large potential market, with about 110 million people in the U.S. living with obesity or overweight and a substantially larger population internationally. Management expects patients to seek different…
• Zepbound Treatment PersistenceImportance 13 · Surprise 6
  Management said Zepbound persistence in covered markets is tracking similarly to the adherence experience previously seen with Trulicity, which had chronic-therapy adherence of roughly 16 to 18 months. Persistence in…
• Competition and Market ShareImportance 11 · Surprise 24
  Ebglyss continued to gain share of new prescriptions in the U.S. specialty dermatology market and management described it as the fastest-growing atopic dermatitis medicine. Jaypirca was the fastest-growing BTK…
• International Incretin CompetitionImportance 11 · Surprise 24
  Lilly said it maintained share and continued to grow in India, Brazil, and Canada despite generic launches. Management described out-of-pocket willingness to pay for incretins as substantial in international markets…